Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pan-beta coronavirus vaccine
- Development stage
- Preclinical
- Lead developer
- Hawaii Biotech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
The Pan-beta coronavirus vaccine is a recombinant subunit vaccine candidate being developed by Hawaii Biotech. It is designed to provide broad-spectrum protection against multiple viruses within the *Betacoronavirus* genus, specifically targeting SARS-CoV, MERS-CoV, and SARS-CoV-2. The vaccine utilizes recombinant protein antigens derived from conserved regions of these viruses to elicit a cross-reactive immune response. This approach aims to provide a proactive defense against existing and potentially emerging beta-coronaviruses by focusing on shared antigenic targets across the viral family.
- Other names
- Hawaii Biotech pan-beta coronavirus vaccine
Beyond the preview
Go deeper on Pan-beta coronavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pan-beta coronavirus vaccine.